Advanced search
Publication Cover
Scandinavian Journal of Urology Volume 49, 2015 - Issue 3
Journal homepage
2,718
Views
30
CrossRef citations to date
0
Altmetric
Original Articles

Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223

Ragnhild NomeDepartment of Medical Biochemistry and
,
Eivor HernesDepartment of Radiology and Nuclear Medicine, and
,
Trond Velde BogsrudDepartment of Radiology and Nuclear Medicine, and;National Resource Centre for Late Effects after Cancer Treatment, Oslo University Hospital
,
Trine BjøroDepartment of Medical Biochemistry and;Faculty of Medicine, University of Oslo, Oslo, NorwayCorrespondence[email protected]
&
Sophie D. FossåDepartement of Nuclear Medicine and PET-Centre, Aarhus University Hospital, Aarhus, Denmark
Pages 211-217 | Received 13 Jun 2014, Accepted 23 Oct 2014, Published online: 17 Dec 2014

Citations (30)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Randi Fuglsang Fonager, Helle Damgaard Zacho, Niels Christian Langkilde, Joan Fledelius, June Anita Ejlersen, Helle Westergreen Hendel, Christian Haarmark, Mette Moe, Jesper Carl Mortensen, Mads Ryø Jochumsen & Lars Jelstrup Petersen. (2018) Prospective comparative study of 18F-sodium fluoride PET/CT and planar bone scintigraphy for treatment response assessment of bone metastases in patients with prostate cancer. Acta Oncologica 57:8, pages 1063-1069.
Read now

Articles from other publishers (29)

Amanjot Sidhu, Nabeeha Khan, Cameron Phillips, Juan Briones, Anil Kapoor, Pawel Zalewski, Neil E. Fleshner, Edward Chow & Urban Emmenegger. (2023) Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer. Journal of Clinical Medicine 12:17, pages 5604.
Crossref
Kim van der Zande, Wim J. G. Oyen, Wilbert Zwart & Andries M. Bergman. (2021) Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation. Cancers 13:17, pages 4346.
Crossref
Pablo Mínguez, Emilia Rodeño, Irache Fernández, Alba Esteban, Lorea Martínez‐Indart & Alfonso Gómez de Iturriaga. (2021) A retrospective study on the potential of 99m Tc‐HDP imaging before therapy for individualizing treatments with 223 Ra‐Cl 2 for metastatic castration resistant prostate cancer . Medical Physics 48:3, pages 1395-1403.
Crossref
I. G. Rusakov, A. A. Gritskevich, T. P. Baitman & S. V. Mishugin. (2020) Еfficiacy and safety of radium-223 in the treatment of metastatic castration-resistant prostate cancer. Meditsinskiy sovet = Medical Council:20, pages 70-82.
Crossref
Jinguo Zhang, Guanzhong Zhai, Bin Yang & Zhenhe Liu. (2020) Computerized Tomography (CT) Updates and Challenges in Diagnosis of Bone Metastases During Prostate Cancer. Current Medical Imaging Formerly Current Medical Imaging Reviews 16:5, pages 565-571.
Crossref
Maria Gazzilli, Rexhep Durmo, Erika Cossalter, Elisabetta Cerudelli, Maria Beatrice Panarotto, Domenico Albano, Francesco Bertagna & Raffaele Giubbini. (2020) Three years’ clinical practice of Radium-223 therapy in patients with symptomatic bone metastases from metastatic castrate-resistant prostate cancer. Nuclear Medicine Communications 41:4, pages 300-307.
Crossref
Megan Ann McNamara, Taofik Oyekunle, Bennett B. Chin, Jorge Oldan, Aseem Anand, Michala Ritz, Lindsey Shantzer, Monika Anand, Andrew J. Armstrong & Daniel J. George. (2019) Patterns of response and progression in bone and soft tissue during and after treatment with radium‐223 for metastatic castrate‐resistant prostate cancer. The Prostate 79:10, pages 1106-1116.
Crossref
Ana María García Vicente & Angel Soriano Castrejón. (2019) Response Assessment of 223Ra Treatment: Should a Fluorocholine PET/CT Be Performed?: Reply. Clinical Nuclear Medicine 44:4, pages 341-342.
Crossref
Elba Etchebehere, Ana Emília Brito, Kalevi Kairemo, Eric Rohren, John Araujo & Homer Macapinlac. (2019) Is interim 18F-fluoride PET/CT a predictor of outcomes after radium-223 therapy?. Radiologia Brasileira 52:1, pages 33-40.
Crossref
Hossein Jadvar & Patrick M Colletti. (2018) 18 F-NaF/ 223 RaCl 2 theranostics in metastatic prostate cancer: treatment response assessment and prediction of outcome . The British Journal of Radiology 91:1091, pages 20170948.
Crossref
Laura Evangelista & Alessandra Zorz. (2018) Re: Response Assessment of 223Ra Treatment: Should a Fluorocholine PET/CT Be Performed?. Clinical Nuclear Medicine 43:11, pages 867-868.
Crossref
Ana María García Vicente & Ángel Soriano Castrejón. (2018) Metabolic imaging in the response assessment of patients treated with 223Ra. What should be. Clinical and Translational Imaging 6:4, pages 317-319.
Crossref
D. Chappard, G. Mabilleau, C. Masson, A. Tahla & E. Legrand. (2018) Metaplastic woven bone in bone metastases: A Fourier-transform infrared analysis and imaging of bone quality (FTIR). Morphologie 102:337, pages 69-77.
Crossref
Marie Øbro Fosbøl, Peter Meidahl Petersen, Andreas Kjaer & Jann Mortensen. (2018) 223 Ra Therapy of Advanced Metastatic Castration-Resistant Prostate Cancer: Quantitative Assessment of Skeletal Tumor Burden for Prognostication of Clinical Outcome and Hematologic Toxicity . Journal of Nuclear Medicine 59:4, pages 596-602.
Crossref
Viviana Frantellizzi, Alessio Farcomeni, Giulia Anna Follacchio, Massimiliano Pacilio, Rosanna Pellegrini, Roberto Pani & Giuseppe De Vincentis. (2017) A 3-variable prognostic score (3-PS) for overall survival prediction in metastatic castration-resistant prostate cancer treated with 223Radium-dichloride. Annals of Nuclear Medicine 32:2, pages 142-148.
Crossref
Marie Øbro Fosbøl, Peter Meidahl Petersen, Gedske Daugaard, Søren Holm, Andreas Kjaer & Jann Mortensen. (2017) Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients. Annals of Nuclear Medicine 32:1, pages 16-21.
Crossref
Daniel Zainfeld & Amir Goldkorn. 2018. Genitourinary Cancers. Genitourinary Cancers 87 104 .
Tai-Lung Cha, Tony Tong-Lin Wu, Nicholas John Vogelzang, Chao-Yuan Huang, Shu-Pin Huang, Chia-Chi Lin, Yen-Chuan Ou, See-Tong Pang, Daniel Heung-Yuan Shen, Wen-Jeng Wu & Wayne Yen-Hwa Chang. (2017) Optimal usage of radium-223 in metastatic castration-resistant prostate cancer. Journal of the Formosan Medical Association 116:11, pages 825-836.
Crossref
Michiel H.F. Poorthuis, Robin W.M. Vernooij, R. Jeroen. A. van Moorselaar & Theo M. de Reijke. (2017) Second-line therapy in patients with metastatic castration-resistant prostate cancer with progression after or under docetaxel: A systematic review of nine randomized controlled trials. Seminars in Oncology 44:5, pages 358-371.
Crossref
Elba Etchebehere, Ana Emilia Brito, Alireza Rezaee, Werner Langsteger & Mohsen Beheshti. (2017) Therapy assessment of bone metastatic disease in the era of 223radium. European Journal of Nuclear Medicine and Molecular Imaging 44:S1, pages 84-96.
Crossref
Vera Wenter, Annika Herlemann, Wolfgang P. Fendler, Harun Ilhan, Natalia Tirichter, Peter Bartenstein, Christian G. Stief, Christian la Fougère, Nathalie L. Albert, Axel Rominger & Christian Gratzke. (2017) Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy. Oncotarget 8:27, pages 44131-44140.
Crossref
Michiel H.F. Poorthuis, Robin W.M. Vernooij, R. Jeroen A. van Moorselaar & Theo M. de Reijke. (2017) First-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of 10 randomised clinical trials. BJU International 119:6, pages 831-845.
Crossref
Sergio Baldari, Giuseppe Boni, Roberto Bortolus, Orazio Caffo, Giario Conti, Giuseppe De Vincentis, Fabio Monari, Giuseppe Procopio, Daniele Santini, Ettore Seregni & Riccardo Valdagni. (2017) Management of metastatic castration-resistant prostate cancer: A focus on radium-223. Critical Reviews in Oncology/Hematology 113, pages 43-51.
Crossref
Andrea K. Miyahira, Michael Morris & Howard R. Soule. (2017) Meeting Report From the Prostate Cancer Foundation Scientific Working Group on Radium-223. The Prostate 77:3, pages 245-254.
Crossref
Giuseppe De Vincentis, Giulia Anna Follacchio, Viviana Frantellizzi, Mauro Liberatore, Francesco Monteleone & Enrico Cortesi. (2016) Prostate-Specific Antigen Flare Phenomenon During 223Ra-Dichloride Treatment for Bone Metastatic Castration-Resistant Prostate Cancer: A Case Report. Clinical Genitourinary Cancer 14:5, pages e529-e533.
Crossref
Dipenkumar Modi, Clara Hwang, Hirva Mamdani, Seongho Kim, Hesham Gayar, Ulka Vaishampayan, Richard Joyrich & Elisabeth I. Heath. (2016) Radium-223 in Heavily Pretreated Metastatic Castrate-Resistant Prostate Cancer. Clinical Genitourinary Cancer 14:5, pages 373-380.e2.
Crossref
Nghi C. Nguyen, Muhammad Shah, Leonard J. Appleman, Rahul Parikh & James M. Mountz. (2016) Radium-223 Therapy for Patients with Metastatic Castrate-Resistant Prostate Cancer: An Update on Literature with Case Presentation. International Journal of Molecular Imaging 2016, pages 1-12.
Crossref
Cyprian Swietaszczyk, Katarzyna Kobus-lachnio & Stanislaw Pilecki. (2022) Toxicity of therapy with Sm-153-EDTMP: To what extend can it be related to the tumor type?. World Journal of Nuclear Medicine 15:01, pages 73-74.
Crossref
Tu Dan, Noelle Williams & Robert B. Den. 2016. Managing Metastatic Prostate Cancer In Your Urological Oncology Practice. Managing Metastatic Prostate Cancer In Your Urological Oncology Practice 171 185 .

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.